Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema

References

• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2(1). doi:10.1186/S40662-015-0026-2
   PubMedGoogle Scholar
• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/DC11-1909
   PubMed Web of Science ®Google Scholar
• Tan GS, Cheung N, Simó R, Cheung GCM, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143–155. doi:10.1016/S2213-8587(16)30052-3
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Zhang C, et al. Diabetic Macular Edema: current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022;11(21). doi:10.3390/CELLS11213362
   Web of Science ®Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539
   PubMed Web of Science ®Google Scholar
• He Y, Ren XJ, Hu BJ, Lam WC, Li XR. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol. 2018;18(1). doi:10.1186/S12886-018-0779-1
   Google Scholar
• Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16(3):365–374. doi:10.1517/14712598.2016.1131265
   PubMed Web of Science ®Google Scholar
• Yuan Q, Liu Y, Gou Y, et al. Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1029584. doi:10.3389/FPHAR.2022.1029584/FULL
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309–317. doi:10.1001/ARCHOPHT.125.3.309
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289–296. doi:10.1001/ARCHOPHTHALMOL.2010.21
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/J.OPHTHA.2014.04.024
   PubMed Web of Science ®Google Scholar
• Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120(9):1843–1851. doi:10.1016/J.OPHTHA.2013.02.018
   PubMed Web of Science ®Google Scholar
• Heng LZ, Sivaprasad S, Crosby-Nwaobi R, et al. A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). Br J Ophthalmol. 2016;100(6):802–807. doi:10.1136/BJOPHTHALMOL-2015-307136
   PubMed Web of Science ®Google Scholar
• Wei W, Chen Y, Hu B, et al. Multicenter, Prospective, Randomized Study of Dexamethasone Intravitreal Implant in Patients with Center-Involved Diabetic Macular Edema in the Asia-Pacific Region. Clin Ophthalmol. 2021;15:4097–4108. doi:10.2147/OPTH.S325618
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–2481. doi:10.1016/J.OPHTHA.2014.07.002
   PubMed Web of Science ®Google Scholar
• Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):463–473. doi:10.1007/S00417-016-3472-1
   PubMed Web of Science ®Google Scholar
• Sharma A, Bellala K, Dongre P, Reddy P. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study. Int Ophthalmol. 2020;40(1):67–72. doi:10.1007/S10792-019-01151-3
   PubMed Web of Science ®Google Scholar
• Ozsaygili C, Duru N. Comparison Of Intravitreal Dexamethasone Implant And Aflibercept In Patients With Treatment-Naive Diabetic Macular Edema With Serous Retinal Detachment. Retina. 2020;40(6):1044–1052. doi:10.1097/IAE.0000000000002537
   PubMed Web of Science ®Google Scholar
• Comet A, Gascon P, Ramtohul P, Donnadieu B, Denis D. INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 12 months follow-up study. Eur J Ophthalmol. 2021;31(2):754–758. doi:10.1177/1120672120930603
   PubMed Web of Science ®Google Scholar
• Totan Y, Güler E, Güraʇaç FB. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment. Curr Eye Res. 2016;41(1):107–113. doi:10.3109/02713683.2014.1002048
   PubMed Web of Science ®Google Scholar
• Kim M, Cho YJ, Lee CH, Lee SC. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. Eye. 2016;30(5):718–725. doi:10.1038/EYE.2016.23
   PubMed Web of Science ®Google Scholar
• Shah SU, Harless A, Bleau L, Maturi RK. Prospective Randomized Subject-Masked Study Of Intravitreal Bevacizumab Monotherapy Versus Dexamethasone Implant Monotherapy In The Treatment Of Persistent Diabetic Macular Edema. Retina. 2016;36(10):1986–1996. doi:10.1097/IAE.0000000000001038
   PubMed Web of Science ®Google Scholar
• Thomas BJ, Yonekawa Y, Wolfe JD, Hassan TS. Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema. Clin Ophthalmol. 2016;10:1679–1684. doi:10.2147/OPTH.S110789
   PubMedGoogle Scholar
• Busch C, Zur D, Fraser-Bell S, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55(8):789–796. doi:10.1007/S00592-018-1151-X
   PubMed Web of Science ®Google Scholar
• Koc H, Alpay A, Ugurbas SH. Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema. BMC Ophthalmol. 2023;23(1):1–7. doi:10.1186/S12886-023-02831-6/TABLES/4
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Liu D, et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: a DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(1):29. doi:10.1001/JAMAOPHTHALMOL.2017.4914
   PubMed Web of Science ®Google Scholar
• Kaya M, Kocak N, Ozturk T, Bolluk V, Ayhan Z, Kaynak S. Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol. Eye. 2021;35(3):777–785. doi:10.1038/S41433-020-0949-2
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018;59(1):1–12. doi:10.1167/IOVS.17-22259
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Nurkkala H, Tamene F, et al. Quantitative Proteomics Analysis of Vitreous Humor from Diabetic Retinopathy Patients. J Proteome Res. 2015;14(12):5131–5143. doi:10.1021/ACS.JPROTEOME.5B00900
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Simó R. Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: an Integrative Approach. Invest Ophthalmol Vis Sci. 2017;58(6):BIO68–BIO75. doi:10.1167/IOVS.17-21769
   PubMed Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, Mansueto S, Vitale DC, Drago F. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci. 2018;138(4):219–232. doi:10.1016/J.JPHS.2018.11.001
   PubMed Web of Science ®Google Scholar
• Urbančič M, Topčić IG. Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective. Clin Ophthalmol. 2019;13:821–828. doi:10.2147/OPTH.S206769
   PubMed Web of Science ®Google Scholar
• Munk MR, Somfai GM, de Smet MD, et al. The Role of Intravitreal Corticosteroids in the Treatment of DME: predictive OCT Biomarkers. Int J Mol Sci. 2022;23(14). doi:10.3390/IJMS23147585
   Web of Science ®Google Scholar
• Vujosevic S, Toma C, Villani E, et al. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol. 2020;57(3):287–296. doi:10.1007/S00592-019-01424-4
   PubMed Web of Science ®Google Scholar
• Cao J, You K, Jin K, et al. Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method. Acta Ophthalmol. 2021;99(1):e19–e27. doi:10.1111/AOS.14514
   PubMed Web of Science ®Google Scholar
• Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for Diabetic Macular Edema. Taiwan J Ophthalmol. 2019;9(4):233–242. doi:10.4103/TJO.TJO_68_19
   PubMedGoogle Scholar
• Suciu CI, Suciu VI, Nicoara SD. Optical Coherence Tomography (Angiography) Biomarkers in the Assessment and Monitoring of Diabetic Macular Edema. J Diabetes Res. 2020;2020:550. doi:10.1155/2020/6655021
   Web of Science ®Google Scholar
• Lee H, Jang H, Choi YA, Kim HC, Chung H. Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018;59(2):715–721. doi:10.1167/IOVS.17-23042
   PubMed Web of Science ®Google Scholar
• Midena E, Pilotto E, Bini S. Hyperreflective Intraretinal Foci as an OCT Biomarker of Retinal Inflammation in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018;59(13):5366. doi:10.1167/IOVS.18-25611
   PubMed Web of Science ®Google Scholar
• Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53(9):5814–5818. doi:10.1167/IOVS.12-9950
   PubMed Web of Science ®Google Scholar
• Sasaki M, Kawasaki R, Noonan JE, Wong TY, Lamoureux E, Wang JJ. Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels. Invest Ophthalmol Vis Sci. 2013;54(8):5544–5549. doi:10.1167/IOVS.13-11849
   PubMed Web of Science ®Google Scholar
• Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132(11):1309–1316. doi:10.1001/JAMAOPHTHALMOL.2014.2350
   PubMed Web of Science ®Google Scholar
• Forooghian F, Stetson PF, Meyer SA, et al. Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina. 2010;30(1):63–70. doi:10.1097/IAE.0B013E3181BD2C5A
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Busch C, et al. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018;125(2):267–275. doi:10.1016/J.OPHTHA.2017.08.031
   PubMed Web of Science ®Google Scholar
• Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013;54(5):3378–3384. doi:10.1167/IOVS.12-11503
   PubMed Web of Science ®Google Scholar
• Sadiq MA, Soliman MK, Sarwar S, et al. Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study. Ophthalmology. 2016;123(2):324–329. doi:10.1016/J.OPHTHA.2015.09.032
   PubMed Web of Science ®Google Scholar
• Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, Montero-Hernández J, Cervera-Taulet E. Effect of Dexamethasone Intravitreal Implant on Visual Acuity and Foveal Photoreceptor Integrity in Macular Edema Secondary to Retinal Vascular Disease. Ophthalmologica. 2021;244(1):83–92. doi:10.1159/000512195
   PubMed Web of Science ®Google Scholar
• Fraser-Bell S, Lim LL, Campain A, et al. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology. 2016;123(6):1399–1401. doi:10.1016/J.OPHTHA.2015.12.012
   PubMed Web of Science ®Google Scholar
• Cornish EE, Teo KYC, Gillies MC, et al. Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema. Br J Ophthalmol. 2023;107(1):79–83. doi:10.1136/BJOPHTHALMOL-2021-319839
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bellocq D, Mathis T. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. Biomed Res Int. 2018;2018:82. doi:10.1155/2018/8289253
   Web of Science ®Google Scholar
• Chi SC, Kang YN, Huang YM. Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis. Sci Rep. 2023;13(1). doi:10.1038/S41598-023-34673-Z
   Web of Science ®Google Scholar
• Patil NS, Mihalache A, Hatamnejad A, Popovic MM, Kertes PJ, Muni RH. Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema: a Meta-Analysis. Ophthalmol Retina. 2023;7(4):289–299. doi:10.1016/J.ORET.2022.10.008
   PubMedGoogle Scholar
• Wells JA. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMOA1414264
   PubMed Web of Science ®Google Scholar
• Wilkins CS, Sobol EK, Lema GMC, Lee JG, Rosen RB, Deobhakta A. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy. Eur J Ophthalmol. 2022;32(5):NP37–NP41. doi:10.1177/11206721211004391
   PubMed Web of Science ®Google Scholar
• De Andrade FL. Simultaneous Therapy with Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema. Med Hypothesis Discov Innov Ophthalmol. 2016;5(1):4.
   PubMedGoogle Scholar
• Saatci AO, Ayhan Z, Engin CD, Saatci AO, Ayhan Z, Engin CD. Simultaneous Intravitreal Ranibizumab and Dexamethasone Implant Administration at the Same Setting in Eyes with Severe Diabetic Macular Edema. Open J Ophthalmol. 2016;6(2):112–118. doi:10.4236/OJOPH.2016.62016
   Google Scholar
• Kaya M, Atas F, Kocak N, Ozturk T, Ayhan Z, Kaynak S. Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: the Month 24 Results from Simultaneously Double Protocol. Curr Eye Res. 2023;48(5):498–505. doi:10.1080/02713683.2023.2168013
   PubMed Web of Science ®Google Scholar
• Lim SY, Wong WM, Seah I, et al. Treat and extend regimen for diabetic macular oedema-a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):303–315. doi:10.1007/S00417-022-05770-Y
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Ruiz-Medrano J. Early-switch versus late-switch in patients with diabetic macular edema: a cost-effectiveness study. Graefe’s Arch Clin Exp Ophthalmol. 2023;261(4):941. doi:10.1007/S00417-022-05892-3
   PubMed Web of Science ®Google Scholar
• Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: a Review. Int J Mol Sci. 2022;23(16). doi:10.3390/IJMS23169424
   PubMed Web of Science ®Google Scholar
• Kuo BL, Singh RP. Brolucizumab for the treatment of diabetic macular edema. Curr Opin Ophthalmol. 2022;33(3):167–173. doi:10.1097/ICU.0000000000000849
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi:10.1016/S0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403–420. doi:10.1089/JOP.2006.0067
   PubMed Web of Science ®Google Scholar
• Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129(7):914–920. doi:10.1001/ARCHOPHTHALMOL.2011.39
   PubMedGoogle Scholar
• Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58(4):291–310. doi:10.1016/J.SURVOPHTHAL.2012.08.003
   PubMed Web of Science ®Google Scholar
• Bandello F, Toni D, Porta M, Varano M. Diabetic retinopathy, diabetic macular edema, and cardiovascular risk: the importance of a long-term perspective and a multidisciplinary approach to optimal intravitreal therapy. Acta Diabetol. 2020;57(5):513–526. doi:10.1007/S00592-019-01453-Z
   PubMed Web of Science ®Google Scholar
• Yoo WS, Seong H, Song C, et al. Role of Chondroitin Sulfate Proteoglycan 5 in Steroid-Induced Cataract. Cells. 2023;12(13):1705. doi:10.3390/CELLS12131705/S1
   PubMed Web of Science ®Google Scholar
• Raghunathan VK, Morgan JT, Park SA, et al. Dexamethasone Stiffens Trabecular Meshwork, Trabecular Meshwork Cells, and Matrix. Invest Ophthalmol Vis Sci. 2015;56(8):4447. doi:10.1167/IOVS.15-16739
   PubMed Web of Science ®Google Scholar
• Maturi RK, Pollack A, Uy HS, et al. Intraocular Pressure In Patients With Diabetic Macular Edema Treated With Dexamethasone Intravitreal Implant In The 3-Year Mead Study. Retina. 2016;36(6):1143–1152. doi:10.1097/IAE.0000000000001004
   PubMed Web of Science ®Google Scholar
• Rezkallah A, Mathis T, Abukhashabah A, et al. Long-Term Incidence And Risk Factors Of Ocular Hypertension Following Dexamethasone-Implant Injections: the Safodex-2 Study. Retina. 2021;41(7):1438–1445. doi:10.1097/IAE.0000000000003080
   PubMed Web of Science ®Google Scholar
• Mello Filho P, Andrade G, Maia A, et al. Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: a Real-World Experience. Ophthalmologica. 2019;241(1):9–16. doi:10.1159/000492132
   PubMed Web of Science ®Google Scholar
• Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39–46. doi:10.1136/BJOPHTHALMOL-2019-313991
   PubMed Web of Science ®Google Scholar
• Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefe’s Arch Clin Exp Ophthalmol. 2018;256(1):59. doi:10.1007/S00417-017-3831-6
   PubMed Web of Science ®Google Scholar
• Xiaodong L, Xuejun X. The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: a Meta-Analysis of Randomized Controlled Trials. J Ophthalmol. 2022;2022:548. doi:10.1155/2022/4007002
   Web of Science ®Google Scholar
• Hosseini K, Matsushima D, Johnson J, et al. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J Ocul Pharmacol Ther. 2008;24(3):301–308. doi:10.1089/JOP.2007.0117
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bandello F, de Smet M, et al. Fluocinolone acetonide implant in diabetic macular edema: international experts’ panel consensus guidelines and treatment algorithm. Eur J Ophthalmol. 2022;32(4):1890–1899. doi:10.1177/11206721221080288
   PubMed Web of Science ®Google Scholar
• Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: the PALADIN Study. Ophthalmology. 2022;129(6):605–613. doi:10.1016/j.ophtha.2022.01.015
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4). doi:10.1016/J.OPHTHA.2010.12.028
   Web of Science ®Google Scholar
• Mathis T, Papegaey M, Ricard C, et al. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: the REALFAc Study. Pharmaceutics. 2022;14(4). doi:10.3390/PHARMACEUTICS14040723
   Web of Science ®Google Scholar
• Fallico M, Maugeri A, Lotery A, et al. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience. Sci Rep. 2021;11(1). doi:10.1038/S41598-021-84362-Y
   PubMed Web of Science ®Google Scholar
• Baillif S, Staccini P, Weber M, et al. Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant. Pharmaceutics. 2022;14(11). doi:10.3390/PHARMACEUTICS14112391
   PubMed Web of Science ®Google Scholar
• Rousseau N, Lebreton O, Masse H, et al. Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study. Ophthalmol Ther. 2023;12(5):2781–2792. doi:10.1007/S40123-023-00749-2
   PubMed Web of Science ®Google Scholar
• Cicinelli MV, Rosenblatt A, Grosso D, et al. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. Eye. 2021;35(12):3232–3242. doi:10.1038/S41433-020-01373-1
   PubMed Web of Science ®Google Scholar
• Coelho J, Malheiro L, Beirão JM, Meireles A, Pessoa B. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes. Clin Ophthalmol. 2019;13:1751–1759. doi:10.2147/OPTH.S201611
   PubMed Web of Science ®Google Scholar
• Klein BEK, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Am J Ophthalmol. 1995;119(3):295–300. doi:10.1016/S0002-9394(14)71170-5
   PubMed Web of Science ®Google Scholar
• Becker C, Schneider C, Aballéa S, et al. Cataract in patients with diabetes mellitus-incidence rates in the UK and risk factors. Eye. 2018;32(6):1028–1035. doi:10.1038/S41433-017-0003-1
   PubMed Web of Science ®Google Scholar
• Kyselova Z, Stefek M, Bauer V. Pharmacological prevention of diabetic cataract. J Diabetes Complications. 2004;18(2):129–140. doi:10.1016/S1056-8727(03)00009-6
   PubMed Web of Science ®Google Scholar
• Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk Factors and Incidence of Macular Edema after Cataract Surgery: a Database Study of 81984 Eyes. Ophthalmology. 2016;123(2):316–323. doi:10.1016/J.OPHTHA.2015.10.001
   PubMed Web of Science ®Google Scholar
• Denniston AK, Chakravarthy U, Zhu H, et al. The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema. Br J Ophthalmol. 2017;101(12):1673–1678. doi:10.1136/BJOPHTHALMOL-2016-309838
   PubMed Web of Science ®Google Scholar
• Dowler JGF, Sehmi KS, Hykin PG, Hamilton AMP. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology. 1999;106(4):663–668. doi:10.1016/S0161-6420(99)90148-3
   PubMed Web of Science ®Google Scholar
• Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema. Curr Opin Ophthalmol. 2012;23(1):26–32. doi:10.1097/ICU.0B013E32834CD5F8
   PubMed Web of Science ®Google Scholar
• Sze AM, Luk FO, Yip TP, Lee GK, Chan CK. Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification. Eur J Ophthalmol. 2015;25(2):168–172. doi:10.5301/EJO.5000523
   PubMed Web of Science ®Google Scholar
• Panozzo GA, Gusson E, Panozzo G, Dalla Mura G. Dexamethasone intravitreal implant at the time of cataract surgery in eyes with diabetic macular edema. Eur J Ophthalmol. 2017;27(4):433–437. doi:10.5301/EJO.5000920
   PubMed Web of Science ®Google Scholar
• Furino C, Boscia F, Niro A, et al. Diabetic Macular Edema And Cataract Surgery: phacoemulsification Combined With Dexamethasone Intravitreal Implant Compared With Standard Phacoemulsification. Retina. 2021;41(5):1102–1109. doi:10.1097/IAE.0000000000002974
   PubMed Web of Science ®Google Scholar
• Fallico M, Lotery A, Maugeri A, et al. Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic macular oedema: a systematic review with meta-analysis. Eye. 2022;36(12):2239–2246. doi:10.1038/S41433-021-01847-W
   PubMed Web of Science ®Google Scholar
• Laursen SB, Erichsen JH, Holm LM, Kessel L. Prevention of macular edema in patients with diabetes after cataract surgery. J Cataract Refract Surg. 2019;45(6):854–869. doi:10.1016/J.JCRS.2019.04.025
   PubMed Web of Science ®Google Scholar
• Barone A, Russo V, Maggiore G, et al. Dexamethasone intravitreal implant in patients with cataract and naïve diabetic macular edema. Eur J Ophthalmol. 2022;32(1):364–371. doi:10.1177/11206721211004395
   PubMed Web of Science ®Google Scholar
• Fallico M, Avitabile T, Castellino N, et al. Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study. Acta Ophthalmol. 2021;99(1):e74–e80. doi:10.1111/AOS.14516
   PubMed Web of Science ®Google Scholar
• Corbelli E, Fasce F, Iuliano L, et al. Cataract surgery with combined versus deferred intravitreal dexamethasone implant for diabetic macular edema: long-term outcomes from a real-world setting. Acta Diabetol. 2020;57(10):1193–1201. doi:10.1007/S00592-020-01509-5
   PubMed Web of Science ®Google Scholar
• Alessio G, Boscia F, Caporossi A, et al. Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements. Eur J Ophthalmol. 2021;31(3):1122–1127. doi:10.1177/1120672120939500
   PubMed Web of Science ®Google Scholar
• García Layana A, Adán A, Ascaso FJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach. Eur J Ophthalmol. 2020;30(5):1042–1052. doi:10.1177/1120672119861623
   PubMed Web of Science ®Google Scholar
• Altan T, Acar N, Kapran Z, Unver YB, Ozdogan S. Transconjunctival 25-gauge sutureless vitrectomy and silicone oil injection in diabetic tractional retinal detachment. Retina. 2008;28(9):1201–1206. doi:10.1097/IAE.0B013E3181853D3C
   PubMed Web of Science ®Google Scholar
• Chaudhry NA. Early Vitrectomy for Severe Vitreous Hemorrhage in Diabetic Retinopathy: four-Year Results of a Randomized Trial: diabetic Retinopathy Study Report 5. Archives of Ophthalmology. 1990;108(7):958–964. doi:10.1001/archopht.1990.01070090060040
   PubMedGoogle Scholar
• Laidlaw DAH. Vitrectomy for diabetic macular oedema. Eye. 2008;22(10):1337–1341. doi:10.1038/EYE.2008.84
   PubMed Web of Science ®Google Scholar
• Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):147–163. doi:10.1007/S00417-008-0980-7
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ishikawa K, Matsumoto T, Yoshida A, Ishibashi T, Kono T. Reduced concentrations of angiogenesis-related factors in vitreous after vitrectomy in patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):799–804. doi:10.1007/S00417-010-1301-5
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–686. doi:10.1016/S0161-6420(02)01969-3
   PubMed Web of Science ®Google Scholar
• Gisladottir S, Loftsson T, Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol. 2009;247(12):1677–1684. doi:10.1007/S00417-009-1141-3
   PubMed Web of Science ®Google Scholar
• Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92(11):1601–1605. doi:10.1016/S0161-6420(85)33838-1
   PubMed Web of Science ®Google Scholar
• Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556–560. doi:10.1097/00006982-200507000-00002
   PubMed Web of Science ®Google Scholar
• Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144(1):124–126. doi:10.1016/J.AJO.2007.02.048
   PubMed Web of Science ®Google Scholar
• Chen YY, Chen PY, Chen FT, Chen YJ, Wang JK. Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema. Int Ophthalmol. 2018;38(1):293–299. doi:10.1007/S10792-017-0462-1
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923. doi:10.1097/IAE.0B013E318206D18C
   PubMed Web of Science ®Google Scholar
• Medeiros MD, Alkabes M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther. 2014;30(9):709–716. doi:10.1089/JOP.2014.0010
   PubMed Web of Science ®Google Scholar
• Bastakis GG, Dimopoulos D, Stavrakakis A, Pappas G. Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema. Eye. 2019;33(3):411–418. doi:10.1038/S41433-018-0219-8
   PubMed Web of Science ®Google Scholar
• Rezkallah A, Malclès A, Dot C, et al. Evaluation of Efficacy and Safety of Dexamethasone Intravitreal Implants of Vitrectomized and Nonvitrectomized Eyes in a Real-World Study. J Ocul Pharmacol Ther. 2018;34(8):596–602. doi:10.1089/JOP.2018.0007
   PubMed Web of Science ®Google Scholar
• Iglicki M, Busch C, Lanzetta P, et al. Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? The VITDEX study. Eye. 2023;37(2):280–284. doi:10.1038/S41433-022-01931-9
   PubMed Web of Science ®Google Scholar
• Giovannini A, Parravano M, Ricci F, Bandello F. Management of diabetic macular edema with intravitreal dexamethasone implants: expert recommendations using a Delphi-based approach. Eur J Ophthalmol. 2019;29(1):82–91. doi:10.1177/1120672118781236
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Baillif S, Couturier A, et al. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study. Eur J Ophthalmol. 2022;32(5):2845–2856. doi:10.1177/11206721211052852
   PubMed Web of Science ®Google Scholar
• Avery RL, Gordon GM. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: a Systematic Review and Meta-analysis. JAMA Ophthalmol. 2016;134(1):21–29. doi:10.1001/JAMAOPHTHALMOL.2015.4070
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bellocq D, Bandello F, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29(6):573–584. doi:10.1177/1120672119857511
   PubMed Web of Science ®Google Scholar